Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01680926

Metabolic Activation With Almased for Type 2 Diabetes Patients (Almased100)

Protein-rich Meal Replacement Significantly Reduces Weight, HbA1c and Daily Insulin Requirement Long-term in Patients With Type 2 Diabetes Mellitus and >100 U Insulin Per Day

Sponsor: Almased Wellness GmbH

Conditions Type 2 Diabetes Mellitus

Interventions Almased

Updated 6 times since 2017 Last updated: Sep 9, 2012 Started: Jul 31, 2009 Primary completion: Feb 28, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01680926, this EARLY_PHASE1 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Almased Wellness GmbH, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Almased Wellness GmbH
West German Center of Diabetes and Health

Data source: West German Center of Diabetes and Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Düsseldorf, Germany